ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
123.906,55
-0,32%
S&P 500
5.460,48
-0,41%
US Dollar vs BRL
5,5936
0,00%
Bitcoin
60.941,03
1,04%
Brent Oil
84,85
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Canadá
  5. CSE
  6. Revive Therapeutics Ltd (RVV)

  7. Revive Therapeutics Ltd (RVV) Notícias

RVV

Revive Therapeutics (RVV)

Revive Therapeutics Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:CSE:RVV
DataHoraFonteTítuloCódigoCompanhia
18/04/202211:26InvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
12/04/202209:00InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
17/01/202211:13InvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsCSE:RVVRevive Therapeutics Ltd
07/01/202210:05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
18/08/202107:00InvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerCSE:RVVRevive Therapeutics Ltd
12/08/202110:56InvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationCSE:RVVRevive Therapeutics Ltd
10/08/202109:52InvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineCSE:RVVRevive Therapeutics Ltd
28/06/202109:00InvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketCSE:RVVRevive Therapeutics Ltd
08/06/202110:12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaCSE:RVVRevive Therapeutics Ltd
17/05/202110:48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripCSE:RVVRevive Therapeutics Ltd
03/05/202110:32InvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19CSE:RVVRevive Therapeutics Ltd
22/04/202109:26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contCSE:RVVRevive Therapeutics Ltd
24/03/202110:15InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
11/02/202110:05InvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramCSE:RVVRevive Therapeutics Ltd
27/01/202110:13InvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentCSE:RVVRevive Therapeutics Ltd
18/01/202111:51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesCSE:RVVRevive Therapeutics Ltd
31/12/202010:30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyCSE:RVVRevive Therapeutics Ltd
22/12/202013:05InvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramCSE:RVVRevive Therapeutics Ltd
31/07/202010:46InvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
23/04/202010:47InvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical TrialCSE:RVVRevive Therapeutics Ltd
 Apresentando as notícias mais relevantes sobre:CSE:RVV

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
TELB4
TELEBRAS PN
BOV
PRIO3
PETRORIO ON
BOV
TECN3
TECHNOS ON
BOV
GOLL4
GOL PN
BOV
BMGB4
BMG PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados